O-36 - STIs & UTIs

Co-Author(s)

• 

  Brian Agan, MD

  Deputy Science Director and HIV Research Director
  Infectious Disease Clinical Research Program, USU/HJF
  Bethesda, Maryland

  Disclosure: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. : Employee (Status: Ongoing)
• KA

  Karthik Akinapelli, BS

  Lead Statistician
  Iterum Therapeutics
  Old Saybrook, Connecticut

  Disclosure: Iterum Therapeutics (Employee)
• SA

  Steven Aronin, MD

  Senior Director, Clinical Development
  Iterum Therapeutics
  Old Saybrook, Connecticut

  Disclosure: Iterum Therapeutics (Employee)
• JB

  Jason Blaylock, MD

  Chief, Infectious Diseases
  Medicine
  Walter Reed National Military Medical Center, Bethesda,
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Helen Boucher, MD

  Director, Tufts Center for Integrated Management of Antimicrobial Resistance
  Tufts Medical Center
  Boston, MA

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• KB

  Katherine Bowden, PhD, BS

  Biologist
  Division of Parasitic Diseases and Malaria
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AB

  Anthony Boyles, MSc

  Senior Data Scientist
  Becton, Dickinson and Company, Franklin Lakes, NJ, USA
  Atlanta, Georgia

  Disclosure: Becton, Dickinson and Company (Employee)GlaxoSmithKline plc. (Other Financial or Material Support, Funding)
• AC

  Amundson Carla, MA

  Study Coordinator
  Minneapolis VA HCS
  Minneapolis, Minnesota

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• RC

  Rhonda Colombo, MD, MHS

  Clinical Research Physician
  Madigan Army Medical Center, Tacoma, WA, Infectious Disease Clinical Research Program, Bethesda, MD, and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
  Tacoma, Washington

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• DD

  Damien Danavall, MSCR, BS

  Biologist
  Division of STD Prevention
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Marisa D'Angeli, MD, MPH

  Medical Epidemiologist
  Healthcare Associated Infections and Antimicrobial Resistance Program
  Washington State Department of Health
  Shoreline, WA

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AD

  Anita Das, PhD

  Project Statistician
  AD Stat Consulting
  Guerneville, CA

  Disclosure: Iterum Therapeutics (Consultant)
• EG

  Eric Garges, MD, MPH

  Physician
  Uniformed Services University of Health Sciences
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Vikas Gupta, PharmD, BCPS

  Director, Clinical Strategy, BD Insights Life Sciences
  Becton, Dickinson and Company
  Franklin Lakes, New Jersey

  Disclosure: Becton, Dickinson and Company (Employee, Shareholder)GlaxoSmithKline plc. (Other Financial or Material Support, Funding)
• SG

  Sarah Gwyn, MSc, BS

  Microbiologist
  Division of Parasitic Diseases and Malaria
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JH

  Jaeyoung Hong, PhD, MS, BS

  Statistician
  Division of STD Prevention
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JJ

  James Johnson, MD

  Professor of Medicine
  Minneapolis VA Medical Center, University of Minnesota,
  Minneapolis, Minnesota

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AJ

  Ashish Joshi, PhD

  Senior Director
  GlaxoSmithKline plc, Collegeville, PA, USA
  Philadelphia, Pennsylvania

  Disclosure: GlaxoSmithKline plc. (Employee, Shareholder)
• HK

  Hema Kapoor, MD; D(ABMM)

  Medical director, Infectious Diseases and Immunology
  Medical Affairs
  Quest Diagnostics
  Secaucus, New Jersey

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• EK

  Ellen Kersh, PhD

  Branch Chief
  Laboratory Reference and Research Branch, Division of STD Prevention
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• RK

  Robert Kirkcaldy, MD, MPH

  Team Lead, Epidemiology Research Team, Division of STD Prevention
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• KK

  Karl Kronmann, MD

  Infectious Disease Physician
  Naval Medical Center
  Portsmouth, Virginia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• MK

  Michael Kuskowski, PhD

  Biostatistician
  University of Minnesota
  Minneapolis, Minnesota

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Tahaniyat Lalani, MBBS

  Research Physician
  IDCRP, HJF, and NMCP
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• DM

  Diana Martin, PhD

  Research Microbiologist
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• RM

  Ryan Maves, MD

  Fellowship Program Director
  Infectious Diseases
  Naval Medical Center San Diego, San Diego, CA and Infectious Disease Clinical Research Program, Bethesda, MD
  San DIego, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• FM

  Fanny Mitrani-Gold, MPH

  Director, Epidemiology
  GlaxoSmithKline plc, Collegeville, PA, USA
  Chicago, Illinois

  Disclosure: GlaxoSmithKline plc. (Employee, Shareholder)
• AM

  Aruni Mulgirigama, MBBS

  Global Medical Affairs Lead
  GlaxoSmithKline plc, Brentford, Middlesex, UK
  Sutton, England, United Kingdom

  Disclosure: GlaxoSmithKline plc. (Employee, Shareholder)
• JO

  Jason Okulicz, MD

  Chief, Infectious Disease Service; USAF ID Consultant
  Brooke Army Medical Center, JBSA Fort Sam Houston, TX
  San Antonio, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• PR

  Peter Rabinowitz, M.D., MPH

  Director, Center for One Health Research
  Environmental and Occupational Health Sciences
  University of Washington
  Seattle, Washington

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• BR

  Brian Raphael, PhD

  Microbiologist
  Division of STD Prevention
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AS

  Ann Salm, M (ASCP), MSc, PhD

  Director, Medical Science Liaison-Infectious Disease and Immunology
  Quest Diagnostics, Incorporated
  Secaucus, New Jersey

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• NS

  Nicole Scangarella-Oman, MS

  Scientific Director
  GlaxoSmithKline Pharmaceuticals
  Collegeville, Pennsylvania

  Disclosure: GlaxoSmithKline plc. (Employee, Shareholder)
• ES

  Emma Schiller, BA

  Research Associate
  Evidera, Bethesda, MD, USA
  Natick, Massachusetts

  Disclosure: Evidera (Employee)GlaxoSmithKline plc. (Other Financial or Material Support, Funding)
• CS

  Christina Schofield, MD

  Infectious Disease Physician
  Madigan Army Medical Center, Tacoma, WA
  Tacoma, Washington

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Barbara Trautner, MD, PhD

  Professor of Medicine
  Infectious Disease
  Michael E DeBakey VA Medical Center
  Houston, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• MT

  Monica Turner, MPH

  Research Associate
  Evidera, Bethesda, MD, USA
  Boston, Massachusetts

  Disclosure: Evidera (Employee)GlaxoSmithKline plc. (Other Financial or Material Support, Funding)
• GU

  Gregory Utz, MD

  Research Physician, Site PI
  Naval Medical Center San Diego, Infectious Disease Clinical Research Program, Bethesda, MD, and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
  San Diego, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• XW

  Xun Wang, MS

  Biostatistician
  Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD
  Rockville, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Scott Weissman, MD

  Associate Professor
  Infectious Diseases
  Seattle Children's Hospital
  Seattle, WA

  Disclosure: MicrobiomX : Advisor or Review Panel member (Status: Ongoing), Shareholder (Status: Ongoing)
• KY

  Kalvin Yu, MD

  Medical Director
  Digital Health
  Becton, Dickinson and Company
  Franklin Lakes, New Jersey

  Disclosure: Becton, Dickinson and Company (Employee)GlaxoSmithKline plc. (Other Financial or Material Support, Funding)
• MZ

  Michael Zelasky, BS

  Head of Biostatistics, Statistical Programming and Data Management
  Iterum Therapeutics
  Old Saybrook, Connecticut

  Disclosure: Iterum Therapeutics (Employee)

Presenting Author(s)

• 

  Gloria Anyalechi, MD MPH

  Medical Epidemiologist
  Division of STD Prevention
  Centers for Disease Control and Prevention
  Atlanta, GA

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Dimitri Drekonja, MD, MS

  Dr.
  Infectious Diseases Section
  Minneapolis Veterans Affairs Health Care System
  Minneapolis, MN

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Michael Dunne, MD

  Chief Scientific Officer
  Iterum Therapeutics
  Old Saybrook, CT

  Disclosure: Iterum Therapeutics (Employee, Shareholder)

  Slides Slides and Audio
• 

  Lauren Frisbie, MPH

  Research Analyst
  University of Washington
  Seattle, WA

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• AG

  Anuradha Ganesan, MBBS, MPH

  Infectious Disease Physician Walter Reed National Military Medical Center
  Infectious Disease Clinical Research Program and the Henry M. Jackson Foundation for the Advancement of Military Medicine and Walter Reed National Military Medical Center
  Bethesda, MD

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Keith Kaye, MD, MPH

  Professor of Internal Medicine, Director of Research, Division of Infectious Diseases
  University of Michigan Medical School
  Ann Arbor, MI

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Amber Martin, BS

  Research scientist
  Evidera, Bethesda, MD, USA
  Waltham, MA

  Disclosure: Evidera: Employee; GlaxoSmithKline plc.: Funding, Other Financial or Material Support

  Slides Slides and Audio

Presentations:

• increasing Odds of Resistance for Subsequent Urinary e. Coli Isolates
  Lauren Frisbie, MPH – University of Washington; Scott Weissman, MD – Seattle Children's Hospital; Hema Kapoor, MD; D(ABMM) – Quest Diagnostics; Marisa A. D'Angeli, MD, MPH – Washington State Department of Health; Ann Salm, M (ASCP), MSc, PhD – Quest Diagnostics, Incorporated; Peter M. Rabinowitz, M.D., MPH – University of Washington
• chlamydia Trachomatis Seroprevalence with a pgp3 Serologic Assay and Association with Pelvic Inflammatory Disease Among Women, United States, 2013–2016
  Gloria Ebelechukwu Anyalechi, MD MPH – Centers for Disease Control and Prevention; Damien Danavall, MSCR, BS – Centers for Disease Control and Prevention; Brian H. Raphael, PhD – Centers for Disease Control and Prevention; Katherine E. Bowden, PhD, BS – Centers for Disease Control and Prevention; Jaeyoung Hong, PhD, MS, BS – Centers for Disease Control and Prevention; Sarah Gwyn, MSc, BS – Centers for Disease Control and Prevention; Diana Martin, PhD – Centers for Disease Control and Prevention; Ellen Kersh, PhD – Centers for Disease Control and Prevention; Robert D. Kirkcaldy, MD, MPH – Centers for Disease Control and Prevention
• Seven vs. 14 Days Treatment Duration for Afebrile Men with Urinary Tract Infections; A Randomized Clinical Trial
  Dimitri M. Drekonja, MD, MS – Minneapolis Veterans Affairs Health Care System; James R. Johnson, MD – Minneapolis VA Medical Center, University of Minnesota,; Amundson Carla, MA – Minneapolis VA HCS; Michael Kuskowski, PhD – University of Minnesota; Barbara Trautner, MD, PhD – Michael E DeBakey VA Medical Center
• Despite the Availability of Free Testing and Care Testing for Extragenital Sexually Transmitted Infections in a Cohort of Hiv-infected Department of Defense Beneficiaries Is Low and Similar to the Rates Observed Nationwide
  Anuradha Ganesan, MBBS, MPH – Infectious Disease Clinical Research Program and the Henry M. Jackson Foundation for the Advancement of Military Medicine and Walter Reed National Military Medical Center; Xun Wang, MS – Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Jason M. Blaylock, MD – Walter Reed National Military Medical Center, Bethesda,; Jason Okulicz, MD – Brooke Army Medical Center, JBSA Fort Sam Houston, TX; Ryan C. Maves, MD – Naval Medical Center San Diego, San Diego, CA and Infectious Disease Clinical Research Program, Bethesda, MD; Rhonda E. Colombo, MD, MHS – Madigan Army Medical Center, Tacoma, WA, Infectious Disease Clinical Research Program, Bethesda, MD, and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD; Gregory Utz, MD – Naval Medical Center San Diego, Infectious Disease Clinical Research Program, Bethesda, MD, and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD; Christina Schofield, MD – Madigan Army Medical Center, Tacoma, WA; Karl Kronmann, MD – Naval Medical Center; Tahaniyat Lalani, MBBS – IDCRP, HJF, and NMCP; Eric Garges, MD, MPH – Uniformed Services University of Health Sciences; Brian Agan, MD – Infectious Disease Clinical Research Program, USU/HJF
• A Systematic Literature Review on the Economic Burden of Illness in Gonorrhea
  Amber Martin, BS – Evidera, Bethesda, MD, USA; Fanny S. Mitrani-Gold, MPH – GlaxoSmithKline plc, Collegeville, PA, USA; Monica Turner, MPH – Evidera, Bethesda, MD, USA; Emma Schiller, BA – Evidera, Bethesda, MD, USA; Ashish V. Joshi, PhD – GlaxoSmithKline plc, Collegeville, PA, USA
• Regional Distribution of Antimicrobial Resistance Among Outpatient Urine E. coli Isolates in US Females ≥ 12 Years of Age: A Multicenter Evaluation in 2019
  Keith S. Kaye, MD, MPH – University of Michigan Medical School; Vikas Gupta, PharmD, BCPS – Becton, Dickinson and Company; Aruni Mulgirigama, MBBS – GlaxoSmithKline plc, Brentford, Middlesex, UK; Ashish V. Joshi, PhD – GlaxoSmithKline plc, Collegeville, PA, USA; Nicole Scangarella-Oman, MS – GlaxoSmithKline Pharmaceuticals; Kalvin Yu, MD – Becton, Dickinson and Company; Anthony Boyles, MSc – Becton, Dickinson and Company, Franklin Lakes, NJ, USA; Fanny S. Mitrani-Gold, MPH – GlaxoSmithKline plc, Collegeville, PA, USA
• Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
  Michael W. Dunne, MD – Iterum Therapeutics; Anita F. Das, PhD – AD Stat Consulting; Michael Zelasky, BS – Iterum Therapeutics; Karthik Akinapelli, BS – Iterum Therapeutics; Helen Boucher, MD – Tufts Medical Center; Steven I. Aronin, MD – Iterum Therapeutics